Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy

International Journal of Hematology

Volumn 95, Issue 6, 2012, Pages 624-631

  Watarai, Hiroshi ^a   Yamada, Daisuke ^a,b   Fujii, Shin Ichiro ^a   Taniguchi, Masaru ^a   Koseki, Haruhiko ^a,b  

^a Institute of Physical and Chemical Research   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Cellular immunotherapy; Embryonic stem (ES) cells; Induced pluripotent stem (iPS) cells; Invariant natural killer T (iNKT) cells

Indexed keywords

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; EMBRYONIC STEM CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; NATURAL KILLER T CELL; PLURIPOTENT STEM CELL; REVIEW;

ANIMALS; EMBRYONIC STEM CELLS; HUMANS; IMMUNOTHERAPY; INDUCED PLURIPOTENT STEM CELLS; LUNG NEOPLASMS; NATURAL KILLER T-CELLS; NEOPLASM STAGING; NEOPLASMS;

EID: 84864966070     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1091-0     Document Type: Review

References (53)

1. Taniguchi M, Harada M, Kojo S, et al. The regulatory role of Va14 NKT cells in innate and acquired immune response. Annu Rev Immunol. 2003;21:483-513. (Pubitemid 37174539)
2. Lantz O, Bendelac A. An invariant T cell receptor a chain is used by a unique subset of major histocompatibility complex class I-specific CD4? and CD4-8- T cells in mice and humans. J Exp Med. 1994;180:1097-106. (Pubitemid 24256622)
3. Bendelac A. Positive selection of mouse NK1? T cells by CD1- expressing cortical thymocytes. J Exp Med. 1995;182:2091-6.
4. Bendelac A, Lantz O, Quimby ME, et al. CD1 recognition by mouse NK1? T lymphocytes. Science. 1995;268:863-5.
5. Exley M, Garcia J, Balk SP, et al. Requirements for CD1d recognition by human invariant Va24?CD4-CD8- T cells. J Exp Med. 1997;186:109-20.
6. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCRmediated activation of Valpha14 NKT cells by glycosylceramides. Science. 1997;278:1626-9. (Pubitemid 27516282)
7. Cui J, Shin T, Kawano T, et al. Requirement for Va14 NKT cells in IL-12-mediated rejection of tumors. Science. 1997;278:1623-6. (Pubitemid 27516281)
8. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol. 2007;25:297-336. (Pubitemid 46697911)
9. Taniguchi M, Seino K, Nakayama T. The NKT cell system: bridging innate and acquired immunity. Nat Immunol. 2003;4: 1164-5. (Pubitemid 37540684)
10. Michel ML, Keller AC, Paget C, et al. Identification of an IL-17- producing NK1.1neg iNKT cell population involved in airway neutrophilia. J Exp Med. 2007;204:995-1001. (Pubitemid 46798144)
11. Tomura M, Yu WG, Ahn HJ, et al. A novel function of Va14?CD4? NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system. J Immunol. 1999;163:93-101. (Pubitemid 29295829)
12. Kitamura H, Iwakabe K, Yahata T, et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med. 1999;189:1121-8.
13. Gonzalez-Aseguinolaza G, de Oliveira C, Tomaska M, et al. α-Galactosylceramide-activated Va14 natural killer T cells mediate protection against murine malaria. Proc Natl Acad Sci USA. 2000;97:8461-6. (Pubitemid 30639695)
14. Trobonjaca Z, Leithäuser F, Möller P, et al. Activating immunity in the liver. I. Liver dendritic cells (but not hepatocytes) are potent activators of IFN-c release by liver NKT cells. J Immunol. 2001;167:1413-22. (Pubitemid 32703139)
15. Stober D, Jomantaite I, Schirmbeck R, et al. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8? T cells in vivo. J Immunol. 2003;170:2540-8. (Pubitemid 36245644)
16. Hermans IF, Silk JD, Gileadi U, et al. NKT cells enhance CD4? and CD8? T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol. 2003;171: 5140-7. (Pubitemid 37432797)
17. Fujii S, Shimizu K, Smith C, et al. Activation of natural killer T cells by a-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med. 2003;198:267-79. (Pubitemid 36987852)
18. Fujii S, Liu K, Smith C, et al. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med. 2004;199:1607-18. (Pubitemid 38821994)
19. Fujii S, Shimizu K, Hemmi H, et al. Innate Va14? natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev. 2007;220:183-98. (Pubitemid 350045564)
20. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of tumor escape phenotypes. Nat Immunol. 2002;3: 999-1005. (Pubitemid 35363649)
21. Yang L, Carbone DP. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res. 2004;92:13-27. (Pubitemid 39458111)
22. Toura I, Kawano T, Akutsu Y, et al. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with a-galactosylceramide. J Immunol. 1999;163:2387-91. (Pubitemid 29399156)
23. Nieda M, Okai M, Tazbirkova A, et al. Therapeutic activation of Va24?Vb11? NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood. 2004;103:383-9. (Pubitemid 38140063)
24. Chang DH, Osman K, Connolly J, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of a-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005;201:1503-17. (Pubitemid 40664093)
25. Ishikawa A, Motohashi S, Ishikawa E, et al. A phase I study of a-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005;11:1910-7. (Pubitemid 40471857)
26. Motohashi S, Ishikawa A, Ishikawa E, et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2006;12: 6079-86. (Pubitemid 44703772)
27. Motohashi S, Nakayama T. Clinical applications of natural killer T cell-based immunotherapy for cancer. Cancer Sci. 2008;99:638-45. (Pubitemid 351448064)
28. Motohashi S, Nagato K, Kunii N, et al. A phase I-II study of a-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol. 2009;182:2492-501.
29. Nakayama N, Fang I, Elliott G. Natural killer and B-lymphoid potential in CD34? cells derived from embryonic stem cells differentiated in the presence of vascular endothelial growth factor. Blood. 1998;91:2283-95. (Pubitemid 28155501)
30. Nakano T, Kodama H, Honjo T. Generation of lymphohematopoietic cells from embryonic stem cells in culture. Science. 1994;265:1098-101. (Pubitemid 24293078)
31. Cho SK, Webber TD, Carlyle JR, et al. Functional characterization of B lymphocytes generated in vitro from embryonic stem cells. Proc Natl Acad Sci USA. 1999;96:9797-802. (Pubitemid 29398812)
32. de Pooter RF, Cho SK, Carlyle JR, et al. In vitro generation of T lymphocytes from embryonic stem cell-derived prehematopoietic progenitors. Blood. 2003;102:1649-53. (Pubitemid 37022556)
33. Schmitt TM, de Pooter RF, Gronski MA, et al. Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro. Nat Immunol. 2004;5:410-7. (Pubitemid 38500090)
34. Hochedlinger K, Jaenisch R. Monoclonal mice generated by nuclear transfer from mature B and T donor cells. Nature. 2002;415:1035-8. (Pubitemid 34193452)
35. Inoue K, Wakao H, Ogonuki N, et al. Generation of cloned mice by direct nuclear transfer from natural killer T cells. Curr Biol. 2005;15:1114-8. (Pubitemid 40841354)
36. Watarai H, Rybouchkin A, Hongo N, et al. Generation of functional NKT cells in vitro from embryonic stem cells bearing rearranged invariant Va14-Ja18 TCRa gene. Blood. 2010;115: 230-7.
37. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-76. (Pubitemid 44233629)
38. Okita K, Ichisaka T, Yamanaka S. Generation of germlinecompetent induced pluripotent stem cells. Nature. 2007;448: 313-7. (Pubitemid 47080336)
39. Wernig M, Meissner A, Foreman R, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007; 448:318-24. (Pubitemid 47080337)
40. Hong H, Takahashi K, Ichisaka T, et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature. 2009;460:1132-5.
41. Schmitt TM, Zúñiga-Pflücker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity. 2002;17:749-56. (Pubitemid 35477794)
42. Benlagha K, Kyin T, Beavis A, et al. A thymic precursor to the NK T cell lineage. Science. 2002;296:553-5. (Pubitemid 34408679)
43. Pellicci DG, Hammond KJ, Uldrich AP, et al. A natural killer T (NKT) cell developmental pathway involving a thymus-dependent NK1.1(-)CD4(?) CD1d-dependent precursor stage. J. J Exp Med. 2002;195:835-44. (Pubitemid 34286755)
44. Hanna J, Markoulaki S, Schorderet P, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell. 2008;133:250-64. (Pubitemid 351508307)
45. Brown M, Rondon E, Rajesh D, et al. Derivation of induced pluripotent stem cells from human peripheral blood T lymphocytes. PLoS One. 2010;5:e11373.
46. Seki T, Yuasa S, Oda M, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell. 2010;7:11-4.
47. Loh YH, Hartung O, Li H, et al. Reprogramming of T cells from human peripheral blood. Cell Stem Cell. 2010;7:15-9.
48. Staerk J, Dawlaty MM, Gao Q, et al. Reprogramming of human peripheral blood cells to induced pluripotent stem cells. Cell Stem Cell. 2010;7:20-4.
49. Watarai H, Nakagawa R, Omori-Miyake M, et al. Methods for detection, isolation and culture of mouse and human invariant NKT cells. Nat Protoc. 2008;3:70-8.
50. Watarai H, Fujii S, Yamada D, et al. Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells. J Clin Invest. 2010;120:2610-8.
51. Seki T, Yuasa S, Oda M, et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell. 2010;7:11-4.
52. Soldner F, Laganiere J, Cheng AW, et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell. 2011;146:318-31.
53. Chen F, Pruett-Miller SM, Huang Y, et al. High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases. Nat Methods. 2011;8:753-5.